Drug Type Antibody drug conjugate (ADC) |
Synonyms A315, MK-1200, SKB 315 + [1] |
Target |
Mechanism CLDN18.2 inhibitors(Claudin 18.2 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), Complement dependent cytotoxicity (CDC) effects |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization KLUS Pharma, Inc.Startup |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 2 | US | 28 Feb 2024 | |
Advanced Malignant Solid Neoplasm | Phase 2 | AU | 28 Feb 2024 | |
Advanced Malignant Solid Neoplasm | Phase 2 | IL | 28 Feb 2024 | |
CLDN18.2 positive Solid Tumors | Phase 1 | CN | 24 Mar 2022 | |
Solid tumor | Phase 1 | CN | - | |
Neoplasms | Preclinical | US | KLUS Pharma, Inc.Startup | - |